More than 300 institutions surveyed Weining health

category:Finance
 More than 300 institutions surveyed Weining health


On November 18 and 20, there were two batches of research on Changhong hi tech, including Chongyang investment, Xingquan fund and Ping An Securities. Changhong High Tech Co., Ltd. landed on the Shanghai Stock Exchange on August 21 this year. During the investigation, the organization mainly focused on the development of the companys thermoplastic elastomer business and the latest production capacity planning of all biodegradable thermoplastic projects.

From the heat of individual stock research, Weining health was the most favored by institutions last week. On November 17, Weining health fell 7.35%. After that days trading, the company held a conference call quickly, attracting more than 300 institutions, including Morgan Stanley, Gaoyi asset, Ruiyuan fund and chaos investment. Weining health shares fell nearly 9% in the week to close at 16.54 yuan / share. It is worth noting that the current stock price level of the company has dropped by nearly 40% compared with the peak in July this year.

On the stock price fluctuation on November 17, Weining Health said that the specific reasons were not clear, but the companys operation was very normal. Looking at the whole year by quarter, it was expected that the stock price would rise quarter by quarter, and the bidding and project promotion were proceeding smoothly. In terms of fundamentals, there is no big disadvantage, and it is developing for the better. In addition, it can be seen from the K-line chart of the company in the past three years that similar situations have been encountered almost every year near the end of the year. It is not ruled out that there is the possibility of short-term fluctuations caused by investors position adjustment at the end of the year.

In addition, the organization also focuses on the companys bidding situation. According to Weining health, affected by the epidemic situation this year, some bidding projects at the hospital and government sides have lagged behind. More than 70% of the companys revenue comes from old users. Although there is a lag in the time of bidding and signing the contract, the implementation of the company is basically not lagging behind. In terms of revenue recognition, revenue cannot be recognized without signing a contract because the bidding process has not been completed, which may have a certain impact on revenue. After entering November, the bidding process of users has been accelerated. Because a lot of funds have already been budget, this years plan will not be postponed to next year, so it is expected that a certain amount of orders will be generated in December.

According to the expectation of next years order revenue, Weining Health said that it was impossible to quantify it at present. But qualitatively, the company is more optimistic about next years expectations. The company said the main reason is: this year is not the disappearance of user demand, but the delay in time. In addition, this year launched a new generation of products, wiex, is confident that it will be launched in large scale next year. Weining Health said that not only does the policy not have a tightening trend, but also may increase investment, so it is expected that adverse changes to the company will not occur next year. Weining health is a provider of healthcare information solutions. According to the financial report, in the first three quarters of this year, the company achieved operating revenue of 1.371 billion yuan, a year-on-year increase of 14.49%; the net profit attributable to the parent was 203 million yuan, a year-on-year decrease of 25.49%. From January to September, the companys core product software sales and technical service business income (accounting for 78.4% of the total operating revenue) increased by 20.71% year-on-year, and the hardware sales business income (accounting for 21.46% of the operating income) increased by 0.65% year-on-year. Source: Securities Times editor in charge: Yang Bin_ NF4368

According to the expectation of next years order revenue, Weining Health said that it was impossible to quantify it at present. But qualitatively, the company is more optimistic about next years expectations. The company said the main reason is: this year is not the disappearance of user demand, but the delay in time. In addition, this year launched a new generation of products, wiex, is confident that it will be launched in large scale next year. Weining Health said that not only does the policy not have a tightening trend, but also may increase investment, so it is expected that adverse changes to the company will not occur next year.